Bonnon, Alexandra;
Kopanidis, Paul;
Kemmis-Betty, Sophia;
Wonderling, David;
de Tisi, Jane;
Miserocchi, Anna;
Sleem, Osama;
... Sen, Arjune; + view all
(2025)
Is resective surgery cost-effective for adults with epilepsy? A cost-utility analysis in a publicly funded healthcare system.
Journal of Neurology, Neurosurgery and Psychiatry
10.1136/jnnp-2025-336197.
(In press).
Preview |
Text
Duncan_JNNP Manuscript 25.5.25 with changes in bold to submit AS_combined.pdf Download (676kB) | Preview |
Abstract
Background Resective epilepsy surgery is an established clinical intervention, but the cost-effectiveness at a national healthcare level is uncertain. This study evaluates the cost-effectiveness of resective epilepsy surgery compared with medical management in adults from national healthcare and personal social services perspectives. Methods A de novo decision analytic model was developed, comprising a 1-year decision tree and lifetime Markov model to evaluate lifetime costs and quality-adjusted life years (QALYs). Data were obtained from UK epilepsy surgery centres to evaluate the costs of preoperative assessment and the probability of undergoing resection after presurgical evaluation. Other clinical inputs were obtained from a systematic literature review. The main outcome of the analysis was the incremental cost-effectiveness ratio (ICER), with a cost-effectiveness threshold set at £20 000 cost per QALY gained. Results Data from 762 patients informed preoperative evaluation costs and the probability of undergoing epilepsy surgery after presurgical evaluation. The total lifetime cost of epilepsy treatment for people who had surgical treatment was £56 911, compared with £32 490 for medical management. Total QALYs per person for surgery were 15.91 and 13.76 for medical management. Resective epilepsy surgery was shown to be cost-effective with an ICER of £11 348 per QALY gained. Conclusions Our data inform and strengthen recommendations to prioritise referral of those with drug-refractory epilepsy to surgical centres. We provide a health economic rationale for the development and support of resective epilepsy surgery programmes across national healthcare systems.
| Type: | Article |
|---|---|
| Title: | Is resective surgery cost-effective for adults with epilepsy? A cost-utility analysis in a publicly funded healthcare system |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1136/jnnp-2025-336197 |
| Publisher version: | https://doi.org/10.1136/jnnp-2025-336197 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | ANTIEPILEPTIC DRUGS, Clinical Neurology, COHORT, DRUG-RESISTANT EPILEPSY, EPILEPSY, HEALTH ECONOMICS, Life Sciences & Biomedicine, MEDICAL COSTS, MORTALITY, Neurosciences & Neurology, PEOPLE, Psychiatry, REFRACTORY EPILEPSY, REMISSION, Science & Technology, Surgery, SURGERY, SURGICAL-TREATMENT, TEMPORAL-LOBE EPILEPSY |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > ICH - Directors Office |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10216947 |
Archive Staff Only
 |
View Item |
